Kinnov Therapeutics

Kinnov Therapeutics

First-in-class therapy for a worldwide market

Menu

  • Company
  • Alcohol addiction
  • R&D / Pipeline
  • Product KT-110
  • Partners / Investors
  • Business strategy
  • News
  • Contact us

Scientific approach of Kinnov Therapeutics acknowledged by scientific community

Scientific approach of Kinnov Therapeutics acknowledged by scientific community

Kinnov Therapeutics original approach to tackle alcohol addiction was recently recognized and distinguished by peers and published in the prestigious peer-reviewed PLOS One journal. This demonstrates our therapeutic strategy is based on solid scientific foundations.  The Combination of Marketed Antagonists

kinnov March 15, 2016March 21, 2016 news Read more

Co-funded by the horizon 2020 programme of the European Union

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction. Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, has been tested in phase 2 clinical trial for alcohol addiction.

Contact Us

Kinnov-Therapeutics

3, allée du titane
45100 Orléans, France


View Larger Map

Pages

  • Addictions: a major Public Health threat
  • Alcohol addiction
  • Business strategy
  • Company
  • Contact us
  • Home
  • Partners / Investors
  • Preclinical trials
  • Product KT-110
  • R&D / Pipeline

Copyright 2020 - Kinnov Therapeutics